// App-Quantinova.ai

PB0920 : Personalizing Prophylaxis with Rurioctocog Alfa Pegol in Previously Treated Patients with Severe Hemophilia A: Outcomes from the Phase 3b CONTINUATION and Phase 3 PROPEL Studies

Researchers

Presenter

  • C. Escuriola-Ettingshausen

Principal Investigators

  • R. Klamroth

  • M. Escobar

  • E.S. Mullins

  • O. Stasyshyn

  • S. Tangada

  • W. Engl

  • I. Honauer

  • H.-Y. Lee

  • P. Chowdary

  • J. Windyga

Medical Centers

  • Haemophilie Zentrum Rhein Main, Morfelden-Walldorf, Germany

  • Vivantes Klinikum Am Friedrichshain, Berlin, Germany

  • University of Texas Health Science Center at Houston - Medical School, Houston, Texas, United States

  • University of Cincinnati College of Medicine and Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States

  • Academy of Medical Sciences of Ukraine, Lviv, Ukraine

  • Baxalta US Inc., a Takeda Company, Cambridge, United States

  • Baxalta Innovations GmbH, a Takeda Company, Vienna, Austria

  • Shire International GmbH, a Takeda company, Zug, Switzerland

  • Katharine Dormandy Haemophilia Centre and Thrombosis Unit, Royal Free NHS Trust, London, United Kingdom

  • Institute of Hematology and Transfusion Medicine, Department of Hemostasis Disorders and Internal Medicine, Warsaw, Poland

Locations

  • Germany

  • United States

  • Ukraine

  • Austria

  • Switzerland

  • United Kingdom

  • Poland

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Hemophilia

Biomarkers

  • N/A

Drug/Treatment

  • rurioctocog alfa

  • Propel

  • FVIII

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT01945593

  • NCT0285960

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved